DRTS Alpha Tau Medical Ltd.
Price Chart
Executive Summary
Alpha Tau announced 100% local disease control in evaluable patients from pooled first-in-human trials of Alpha DaRT for pancreatic cancer, presented at DDW 2026. The favorable safety and efficacy data in heavily pre-treated patients represent a significant milestone for the company's lead product candidate.
Actionable Insight
The strong efficacy and safety data could drive near-term upside. Monitor for updates on the IMPACT trial and potential regulatory filings. Insider trading patterns and analyst upgrades may provide further signals.
Key Facts
- 100% local disease control in 19 evaluable patients (79% stable disease, 21% partial response)
- Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
- First presentation of Alpha DaRT at a major gastroenterology conference (DDW 2026)
- Treatment delivered via EUS, designed for integration into standard GI workflow
- Ongoing U.S. multicenter pancreatic cancer IMPACT trial
Financial Impact
Positive sentiment boost; potential future revenue if approved, but no current financial impact
Risk Factors
- Data is from early-stage trials; larger studies may not replicate results
- Alpha DaRT is not yet approved for commercial use in the U.S.
- Biotech volatility; stock may have priced in expectations
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
Press Release
| $10.58 $10.29 | ▼ −2.74% | ▼ −3.14% | $9.28 (−12.29%) |
|
May 11, 2026
29d ago
|
Press Release
| $10.34 $9.88 | ▼ −4.45% | ▼ −4.31% | $9.28 (−10.25%) |
|
May 8, 2026
4w ago
|
Press Release
| $8.51 $10.34 | ▲ +21.50% | ▲ +21.27% | $9.28 (+9.05%) |
|
May 5, 2026
5w ago
|
Press Release
| $7.39 $7.59 | ▲ +2.71% | ▲ +1.32% | $9.28 (+25.58%) |
|
May 4, 2026
5w ago
|
Press Release
| $7.53 $7.39 | ▼ −1.86% | ▼ −2.65% | $9.28 (+23.24%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $7.91 $7.30 | ▼ −7.71% | ▼ −7.23% | $9.28 (+17.32%) |
|
Apr 23, 2026
6w ago
|
Press Release
| $7.98 $8.09 | ▲ +1.38% | ▲ +0.59% | $9.28 (+16.29%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $6.84 $7.04 | ▲ +2.92% | ▲ +3.03% | $9.28 (+35.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access